In natalizumab-treated patients without previous immunosuppressive treatment, the JCV antibody index is used to stratify PML risk. A high index value indicates that the risk to develop PML is significantly elevated, although probably about 99% of patients with this index value will not develop PML. This minireview aimed to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML.
| INTRODUCTION
Progressive multifocal leukoencephalopathy (PML) is a lifethreatening disease caused by a failure of the immune system to control a brain infection with JC polyomavirus (JCV). In the 20 th century, PML was mainly seen in patients with haematological malignancies and AIDS. During the last decade, the occurrence of PML has increasingly become associated with the use of immunosuppressive or immunomodulating drugs. 1,2 PML has especially plagued multiple sclerosis (MS) patients that are treated with natalizumab. In June 2017, more than 730 cases were registered. 3 The mortality rate of PML depends on the underlying condition and is especially high in patients with a haematological malignancy. In natalizumab-treated patients, the overall mortality rate is about 24%, but appears to decrease rapidly due to earlier recognition of the disease. 4 The threat of a possible debilitating complication due to MS treatments remains a challenge for both patients and physicians, because it is still impossible to predict who will develop PML. In natalizumab-treated patients, the measurement of antibodies to JCV has become a useful tool to estimate PML risk. This minireview aims to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML.
| JCV INFECTION AND PERSISTENCE
JCV is a polyomavirus found exclusively in humans. Multiple, closely related JCV genotypes exist and are associated with their own geographic region. 5 It appears to be possible to be infected with more than one genotype. Viral transmission is thought to occur mainly via the urine-oral route. 6 During primary infection, the virus has a brief period to disseminate in the body before the adaptive immune re- There is evidence for persistent replication in the kidneys in about a third of infected people, because they secrete JCV virus asymptomatically in their urine. 5 It is likely that persistent replication can also occur at other sites, because JCV DNA can be detected in blood of deeply immunocompromised people. In immunocompetent people, however, JCV viraemia is very rare. In addition, it has been observed that several cell types, including oligodendrocytes in the brain, can Adequate CD8+ cell function also appears to be important to control JCV infections, as several studies have shown that a lack of anti-JCV activity of CD8+ cells is associated with an unfavourable prognosis of PML. [13] [14] [15] In a recent review of PML cases in patients that used fumaric acids, such as dimethylfumarate, very low CD8+ cell counts in combination with low CD4+ cell counts were associated with the occurrence of PML (see Table 1 ). 18 In the lymph nodes, T cells either recognize these antigens or antigens derived from peripheral tissues. 19 They may subsequently become activated and enter the brain through the microvascular endothelium of the blood-brain barrier or through the choroid plexus via CSF into the brain parenchyma by a route that is not well understood. 20, 21 After resolution of the infection, it is thought that (tissue-resident) memory T cells remain in the brain parenchyma for surveillance, or monitor the CNS by trafficking through CSF within the subarachnoid space, where they encounter a broad spectrum of APCs. 22, 23 In the defence against CNS infections, it is essential that trafficking of immune cells from the periphery to the CNS is unimpeded.
This might explain why drugs that interfere with leucocyte migration, such as natalizumab, efalizumab and fingolimod, are associated with PML, although additional effects of these drugs on the immune system could also be involved. Berger et al recently provided a PML risk stratification for disease modifying therapies used in the treatment of multiple sclerosis (MS).
1 Table 1 provides a short overview of MS therapies, their effect on the immune system and their risk to cause reactivation of latent viral infections, including the risk for PML.
| THE ROLE OF ANTIBODIES TO JCV TO CONTROL INFECTION
The observation that a high antibody index in the JCV® DxSelect™ test 1) The neutralizing capability of antibodies refers to their ability to prevent viral infection of an otherwise susceptible cell. 32 Antibodies on the cell surface may also prevent viral escape by interfering with the enzymatic activity of local viral proteins or by preventing budding from the cell surface. 33 It is unknown whether these antibody properties are relevant for JCV infections. However, this seems highly unlikely with respect to the latter two functions, because JCV particles are not formed at the cell surface.
3) Finally, antibodies can capture and aggregate virus particles, which subsequently leads to opsonization and destruction by phagocytes.
It is unknown how relevant this process is in the control of JCV infections.
To summarize, the humoral immune response may play a role in the prevention of primary JCV infections and in the control of acquired infections, but its importance remains uncertain. To date, it appears that the immunological control of JCV infections depends primarily on the cell-mediated adaptive immune response, as is the case with many viral infections. This is supported by the fact that high JCV antibody titres do not protect against PML but are rather associated with an increased risk, and by the very small number of PML cases in patients with primary antibody deficiencies. 34, 35 To the best of our knowledge, only three cases of PML in patients with a selective humoral immunodeficiency have been described, including a 4-year-old child with hypogammaglobulinaemia and nearly undetectable CD20+ B cells and a 37-year-old man with X-linked agammaglobulinaemia (XLA) that received regular monthly intravenous immunoglobulins. [36] [37] [38] However, even in these cases, it cannot be excluded that the B-cell deficiency itself contributed to the development of PML, irrespective of the hypogammaglobulinaemia. In contrast, many XLA patients developed chronic and eventually fatal enterovirus encephalitis before intravenous administration of immunoglobulins became standard of care, which shows that antibodies can have a pivotal role in the control of some viral infections. 39 differently to reduce the false-negative rate, but this would be at the expense of the rate of false-positive results. As can be expected, PML can occur in JCV infected patients with a negative JCV antibody test, but this is very rare. 41 In MS patients without previous use of immunosuppressive drugs, the time of natalizumab exposure in combination with the STRATIFY JCV index value provide an estimate of the chance to develop PML. 35 An index above 0.9 is associated with an increasing risk for PML. 35, 42, 43 It is important to note that the PML risk associated with a high index value may be much higher than previously estimated, because risk estimates were not corrected for the patients that stopped treatment within a given epoch (in years), but were counted as if they received treatment for the entire period. 43 To date, the relationship between the STRATIFY JCV index and PML has only been validated for natalizumab-treated patients, but it might also be a marker in other patient groups. 44 It was, for example, found that in HIV patients the antibody titres also increased before PML be- 29 There is, however, evidence that the antibody index value may rise over time (associated with ageing) and upon prolonged natalizumab exposure. 29, [45] [46] [47] Evidence is still conflicting, and more studies are needed to confirm these associations.
| THE ROLE OF JCV-SPECIFIC ANTIBODIES TO STRATIFY RISK FOR PML
Although the STRATIFY JCV index is a useful tool with high sensitivity, the specificity of a high index value to predict PML is low as about 40% of MS patients are JCV+ with index values of >0.9
(30% > 1.5). 35 This means that over 99% of patients with a high antibody index will probably not develop PML. 1, 43 Here are some general considerations that should be kept in mind when interpreting levels of antibodies (see Table 2 ). First, the antibody titre is often related to the time to infection. When the pathogen was encountered in the distant past, antibody levels may have dropped. In contrast, a recent primary infection or re-infection boosts antibody levels. Antibody levels can also be boosted by viral reactivation. A high antibody titre may therefore point to a recent (re)infection or reactivation.
Second, antibody tests may detect cross-reacting antibodies and thus may be false positive. This is a challenge for developers of serologic assays and can be difficult to prevent when pathogens are closely related and have similar antigens. A prime candidate for crossreactivity in JCV assays would be the antibodies to closely related BKV. In the STRATIFY JCV test, the level of cross-reactivity with antibodies to BKV appears to be minimal, but this may not be the case with other assays. 48 The STRATIFY JCV test insert further mentions that antibodies to C. pneumonia, CMV, HIV or HSV-1 may cross-react in the assay.
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T A B L E 2 Factors that may influence antibody levels to a specific pathogen
Factor Explanation
Timing to infection High antibody titre after recent exposure to that pathogen (either as a primary infection or re-exposure, reinfection or reactivation of a latent pathogen). Antibody titres may drop after some time or disappear entirely 
| INTRATHECAL ANTIBODIES TO JCV TO DIAGNOSE PML
PML is generally diagnosed by brain imaging in combination with JCV DNA detection in CSF or brain tissue by PCR. Unfortunately, the sensitivity of JCV PCR in CSF is comparatively low. In a review of 326 published drug-associated PML reports, the PCR for JCV was positive in only 63.5% of the first CSF samples. 2 Therefore, follow-up CSF taps or brain biopsy was needed for final laboratory diagnosis. The high amount of negative PCR results is not due to a lack of technical sensitivity of the assays used, but because in PML the majority of virus resides in the white matter of the brain and not in the CSF. As can be expected from the experience with other infections in the CNS, JCV infections in the brain also lead to intrathecal antibody production.
Several recent studies of PML cases demonstrate that the detection of intrathecal antibodies to JCV may precede detection of JCV DNA in CSF. 54, 55 The intrathecal antibody production to JCV is measured by calculating the CSF/serum indexes for albumin, total IgG and anti-JCV IgG, according to the method introduced by dr. H. Reiber. 56 With these, the JCV-specific CSF/serum antibody index can be calculated, which is a different index than the STRATIFY JCV index. A positive antibody index with a value above 1.5 provides evidence for intrathecal antibody production, while a value of 1 or lower would indicate that the amount of JCV antibodies in CSF is the result of diffusion from the blood or disturbance of the blood-CSF barrier. 54 It is very unfortunate that this test is not widely available, because it may help diagnose PML at an early stage and may also prevent multiple CSF taps or even a brain biopsy. Because early diagnosis is associated with a favourable diagnosis, we think the JCV CSF/serum index should be included in any CSF test for JCV.
| CONCLUSIONS AND PERSPECTIVE
To date, the measurement of JCV antibodies to stratify PML risk has been restricted to natalizumab-treated patients without pretreatment with immunosuppressive drugs. However, with the evidence that high antibody levels can reflect a large viral reservoir, the antibody index may also have a predictive value in other patient groups that are at risk for PML. In addition, high antibody titres to BKV appear to correlate with protection against PML. Perhaps the level of BKV antibodies can be used to estimate PML risk more precisely. Further research is needed to validate these hypotheses.
Measurements of intrathecal JCV antibodies also have a role to diagnose PML, because intrathecal antibody production is indicative of a CNS infection with JCV.
